Gelesis Holdings, Inc. (GLSHQ)

Market Cap	73.00 -100.0%
Revenue (ttm)	12.14M -45.8%
Net Income	-51.67M
EPS	-0.71
Shares Out	73.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	126,011
Average Volume	27,380
Open	0.0000
Previous Close	n/a
Day's Range	0.0000 - 0.0000
52-Week Range	0.0000 - 0.0001
Beta	3,447.77
RSI	45.97
Earnings Date	n/a

About Gelesis Holdings

Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporate...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 93
• Stock Exchange: OTCMKTS
• Ticker Symbol: GLSHQ

Financial Performance

In 2022, Gelesis Holdings's revenue was $25.77 million, an increase of 130.37% compared to the previous year's $11.19 million. Losses were -$95.06 million, -49.40% less than in 2021.